User Fee Formula Does Not Account For Greater Number Of Industry-Requested Meetings, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
An agency white paper reports that increasing drug development costs and thinning pipelines are prompting more companies to seek formal advice from FDA in the IND phase, increasing the agency’s workload.